Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin

Carine Robert, Pratik K. Nagaria, Nisha Pawar, Adeoluwa Adewuyi, Ivana Gojo, David J Meyers, Philip A. Cole, Feyruz V. Rassool

Research output: Contribution to journalArticle

Abstract

Histone deacetylase inhibitors (HDACi) induce acetylation of histone and non-histone proteins, and modulate the acetylation of proteins involved in DNA double-strand break (DSB) repair. Non-homologous end-joining (NHEJ) is one of the main pathways for repairing DSBs. Decreased NHEJ activity has been reported with HDACi treatment. However, mechanisms through which these effects are regulated in the context of chromatin are unclear. We show that pan-HDACi, trichostatin A (TSA), causes differential acetylation of DNA repair factors Ku70/Ku80 and poly ADP-ribose polymerase-1 (PARP1), and impairs NHEJ. Repair effects are reversed by treatments with p300/CBP inhibitor C646, with significantly decreased acetylation of PARP1. In keeping with these findings, TSA treatment significantly increases PARP1 binding to DSBs in chromatin. Notably, AML patients treated with HDACi entinostat (MS275) in vivo also show increased formation of poly ADP-ribose (PAR) that co-localizes with DSBs. Further, we demonstrate that PARP1 bound to chromatin increases with duration of TSA exposure, resembling PARP "trapping". Knockdown of PARP1 inhibits trapping and mitigates HDACi effects on NHEJ. Finally, combination of HDACi with potent PARP inhibitor talazoparib (BMN673) shows a dose-dependent increase in PARP "trapping", which correlates with increased apoptosis. These results provide a mechanism through which HDACi inhibits deacetylation and increases binding of PARP1 to DSBs, leading to decreased NHEJ and cytotoxicity of leukemia cells.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalLeukemia Research
Volume45
DOIs
StatePublished - Jun 1 2016

Fingerprint

Histone Deacetylase Inhibitors
Double-Stranded DNA Breaks
Acetylation
Chromatin
trichostatin A
Poly Adenosine Diphosphate Ribose
Poly (ADP-Ribose) Polymerase-1
DNA Repair
Histones
Leukemia
Proteins
Therapeutics
Apoptosis
1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione

Keywords

  • DSB repair
  • HDAC
  • NHEJ
  • PARP1

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. / Robert, Carine; Nagaria, Pratik K.; Pawar, Nisha; Adewuyi, Adeoluwa; Gojo, Ivana; Meyers, David J; Cole, Philip A.; Rassool, Feyruz V.

In: Leukemia Research, Vol. 45, 01.06.2016, p. 14-23.

Research output: Contribution to journalArticle

Robert, Carine ; Nagaria, Pratik K. ; Pawar, Nisha ; Adewuyi, Adeoluwa ; Gojo, Ivana ; Meyers, David J ; Cole, Philip A. ; Rassool, Feyruz V. / Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin. In: Leukemia Research. 2016 ; Vol. 45. pp. 14-23.
@article{78b084ce7e8f4f7f88f3331a8ff04ad9,
title = "Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin",
abstract = "Histone deacetylase inhibitors (HDACi) induce acetylation of histone and non-histone proteins, and modulate the acetylation of proteins involved in DNA double-strand break (DSB) repair. Non-homologous end-joining (NHEJ) is one of the main pathways for repairing DSBs. Decreased NHEJ activity has been reported with HDACi treatment. However, mechanisms through which these effects are regulated in the context of chromatin are unclear. We show that pan-HDACi, trichostatin A (TSA), causes differential acetylation of DNA repair factors Ku70/Ku80 and poly ADP-ribose polymerase-1 (PARP1), and impairs NHEJ. Repair effects are reversed by treatments with p300/CBP inhibitor C646, with significantly decreased acetylation of PARP1. In keeping with these findings, TSA treatment significantly increases PARP1 binding to DSBs in chromatin. Notably, AML patients treated with HDACi entinostat (MS275) in vivo also show increased formation of poly ADP-ribose (PAR) that co-localizes with DSBs. Further, we demonstrate that PARP1 bound to chromatin increases with duration of TSA exposure, resembling PARP {"}trapping{"}. Knockdown of PARP1 inhibits trapping and mitigates HDACi effects on NHEJ. Finally, combination of HDACi with potent PARP inhibitor talazoparib (BMN673) shows a dose-dependent increase in PARP {"}trapping{"}, which correlates with increased apoptosis. These results provide a mechanism through which HDACi inhibits deacetylation and increases binding of PARP1 to DSBs, leading to decreased NHEJ and cytotoxicity of leukemia cells.",
keywords = "DSB repair, HDAC, NHEJ, PARP1",
author = "Carine Robert and Nagaria, {Pratik K.} and Nisha Pawar and Adeoluwa Adewuyi and Ivana Gojo and Meyers, {David J} and Cole, {Philip A.} and Rassool, {Feyruz V.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.leukres.2016.03.007",
language = "English (US)",
volume = "45",
pages = "14--23",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin

AU - Robert, Carine

AU - Nagaria, Pratik K.

AU - Pawar, Nisha

AU - Adewuyi, Adeoluwa

AU - Gojo, Ivana

AU - Meyers, David J

AU - Cole, Philip A.

AU - Rassool, Feyruz V.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Histone deacetylase inhibitors (HDACi) induce acetylation of histone and non-histone proteins, and modulate the acetylation of proteins involved in DNA double-strand break (DSB) repair. Non-homologous end-joining (NHEJ) is one of the main pathways for repairing DSBs. Decreased NHEJ activity has been reported with HDACi treatment. However, mechanisms through which these effects are regulated in the context of chromatin are unclear. We show that pan-HDACi, trichostatin A (TSA), causes differential acetylation of DNA repair factors Ku70/Ku80 and poly ADP-ribose polymerase-1 (PARP1), and impairs NHEJ. Repair effects are reversed by treatments with p300/CBP inhibitor C646, with significantly decreased acetylation of PARP1. In keeping with these findings, TSA treatment significantly increases PARP1 binding to DSBs in chromatin. Notably, AML patients treated with HDACi entinostat (MS275) in vivo also show increased formation of poly ADP-ribose (PAR) that co-localizes with DSBs. Further, we demonstrate that PARP1 bound to chromatin increases with duration of TSA exposure, resembling PARP "trapping". Knockdown of PARP1 inhibits trapping and mitigates HDACi effects on NHEJ. Finally, combination of HDACi with potent PARP inhibitor talazoparib (BMN673) shows a dose-dependent increase in PARP "trapping", which correlates with increased apoptosis. These results provide a mechanism through which HDACi inhibits deacetylation and increases binding of PARP1 to DSBs, leading to decreased NHEJ and cytotoxicity of leukemia cells.

AB - Histone deacetylase inhibitors (HDACi) induce acetylation of histone and non-histone proteins, and modulate the acetylation of proteins involved in DNA double-strand break (DSB) repair. Non-homologous end-joining (NHEJ) is one of the main pathways for repairing DSBs. Decreased NHEJ activity has been reported with HDACi treatment. However, mechanisms through which these effects are regulated in the context of chromatin are unclear. We show that pan-HDACi, trichostatin A (TSA), causes differential acetylation of DNA repair factors Ku70/Ku80 and poly ADP-ribose polymerase-1 (PARP1), and impairs NHEJ. Repair effects are reversed by treatments with p300/CBP inhibitor C646, with significantly decreased acetylation of PARP1. In keeping with these findings, TSA treatment significantly increases PARP1 binding to DSBs in chromatin. Notably, AML patients treated with HDACi entinostat (MS275) in vivo also show increased formation of poly ADP-ribose (PAR) that co-localizes with DSBs. Further, we demonstrate that PARP1 bound to chromatin increases with duration of TSA exposure, resembling PARP "trapping". Knockdown of PARP1 inhibits trapping and mitigates HDACi effects on NHEJ. Finally, combination of HDACi with potent PARP inhibitor talazoparib (BMN673) shows a dose-dependent increase in PARP "trapping", which correlates with increased apoptosis. These results provide a mechanism through which HDACi inhibits deacetylation and increases binding of PARP1 to DSBs, leading to decreased NHEJ and cytotoxicity of leukemia cells.

KW - DSB repair

KW - HDAC

KW - NHEJ

KW - PARP1

UR - http://www.scopus.com/inward/record.url?scp=84962764054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962764054&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.03.007

DO - 10.1016/j.leukres.2016.03.007

M3 - Article

VL - 45

SP - 14

EP - 23

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -